Home » Stocks » FLXN

Flexion Therapeutics, Inc. (FLXN)

Stock Price: $9.47 USD 0.56 (6.29%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
After-hours: $9.49 +0.02 (0.21%) Jun 15, 4:42 PM
Market Cap 470.95M
Revenue (ttm) 90.01M
Net Income (ttm) -105.46M
Shares Out 49.84M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $9.47
Previous Close $8.91
Change ($) 0.56
Change (%) 6.29%
Day's Open 8.95
Day's Range 8.84 - 9.51
Day's Volume 534,955
52-Week Range 6.71 - 14.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

1 day ago - GlobeNewsWire

BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO...

6 days ago - GlobeNewsWire

BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. T...

1 week ago - GlobeNewsWire

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Other stocks mentioned: ASLN, BLRX, ICMB, MRNS
1 week ago - Zacks Investment Research

BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

1 week ago - GlobeNewsWire

BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an ana...

1 month ago - GlobeNewsWire

Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 40.00% year over year to ($0.57), which missed ...

1 month ago - Benzinga

BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.

1 month ago - GlobeNewsWire

On Wednesday, May 12, Flexion Therapeutics (NASDAQ:FLXN) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

1 month ago - Benzinga

BURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units. ...

1 month ago - GlobeNewsWire

BURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. fina...

1 month ago - GlobeNewsWire

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BURLINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present preliminary data from a Phase 1 single ascending dose (SAD) trial of FX201 at the 2021 America...

1 month ago - GlobeNewsWire

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Other stocks mentioned: ALXN, ATVI, BKR, BMRN, ESPR, FATE, RETA
1 month ago - 24/7 Wall Street

BURLINGTON, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net s...

2 months ago - GlobeNewsWire

BURLINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an a...

2 months ago - GlobeNewsWire

With the trading day approaching halfway over, the broad markets were trading marginally positive.

Other stocks mentioned: ANF, PFE, TEVA, DHR, JAZZ
2 months ago - 24/7 Wall Street

BURLINGTON, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in a Phase 1b proof-of-concept trial evaluating the safe...

2 months ago - GlobeNewsWire

BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an a...

3 months ago - GlobeNewsWire

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.09% and -1.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 57.47% over the past year to ($0.37), which ...

3 months ago - Benzinga

BURLINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended Dec...

3 months ago - GlobeNewsWire

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close...

3 months ago - GlobeNewsWire

The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot and ankle-r...

3 months ago - Benzinga

BURLINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) appl...

3 months ago - GlobeNewsWire

BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

3 months ago - GlobeNewsWire

Flexion Therapeutics Inc (NASDAQ: FLXN) plans to advance FX201 into the high dose cohort of Phase 1 dose-escalation trial, evaluating the safety and tolerability of FX201 for the treatment of osteoarthr...

3 months ago - Benzinga

- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain - Sheryl Swoopes, WNBA Legend, Basketball Hall of ...

4 months ago - GlobeNewsWire

Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the company continu...

4 months ago - Seeking Alpha

BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, ...

5 months ago - GlobeNewsWire

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

5 months ago - GlobeNewsWire

BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

6 months ago - GlobeNewsWire

BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock units. T...

6 months ago - GlobeNewsWire

BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

7 months ago - GlobeNewsWire

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.

7 months ago - GlobeNewsWire

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. fin...

7 months ago - GlobeNewsWire

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET

8 months ago - GlobeNewsWire

BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the ...

8 months ago - GlobeNewsWire

BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. Th...

8 months ago - GlobeNewsWire

BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an...

9 months ago - GlobeNewsWire

BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation tr...

9 months ago - GlobeNewsWire

BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an...

9 months ago - GlobeNewsWire

BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics ...

9 months ago - GlobeNewsWire

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2020.

10 months ago - GlobeNewsWire

A Relative Strength Rating upgrade for Flexion Therapeutics shows improving technical performance. Will it continue?

10 months ago - Investors Business Daily

BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highligh...

10 months ago - GlobeNewsWire

About FLXN

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the kne... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 12, 2014
CEO
Michael Clayman
Employees
257
Stock Exchange
NASDAQ
Ticker Symbol
FLXN
Full Company Profile

Financial Performance

In 2020, FLXN's revenue was $85.55 million, an increase of 17.26% compared to the previous year's $72.96 million. Losses were -$113.71 million, -24.08% less than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for FLXN stock is "Buy." The 12-month stock price forecast is 19.15, which is an increase of 102.22% from the latest price.

Price Target
$19.15
(102.22% upside)
Analyst Consensus: Buy